Back to Search
Start Over
Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.
- Source :
- Tohoku Journal of Experimental Medicine; Oct2023, Vol. 261 Issue 2, p123-127, 5p
- Publication Year :
- 2023
-
Abstract
- The presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) against anti-HLA-A, -B, -C, and -DRB1 in HLA-mismatched hematopoietic stem cell transplantation (HSCT) is associated with graft failure. DSAs against HLA-A, -B, -C, and -DRB1 with a mean fluorescence intensity (MFI) of greater than > 1,000 was shown to increase the risk of graft failure in single-unit umbilical cord blood transplantation (UCBT). Nevertheless, the impact of DSAs against HLA-DP or -DQ on transplantation outcomes is not fully understood. In this report, we present a case of UCBT in a patient with myelodysplastic syndrome who was positive for DSAs against HLA-DP with MFI of 1,263 before UCBT but successfully achieved neutrophil engraftment. If HLA-DP or -DQ is mismatched in UCBT, evaluating DSAs against HLA-DP or -DQ is crucial to avoid graft failure. However, the criteria for DSAs against HLA-A, -B, -C, and -DRB1 may not be directly applicable to those against HLA-DP or -DQ. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00408727
- Volume :
- 261
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Tohoku Journal of Experimental Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 173245527
- Full Text :
- https://doi.org/10.1620/tjem.2023.J063